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Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) clones have caused a huge worldwide epidemic of hospital-acquired infections over
the past 20–30 years and continue to evolve, including the advent of virulent community strains. The burden on healthcare services
is highly signiﬁcant, in particular because MRSA has not replaced susceptible staphylococcal infection but is an additional problem.
Treatment strategies for MRSA are suboptimal and compromise the care of patients. MRSA is associated with serious morbidity and
mortality, both within and without hospitals. Although the literature on the costs of MRSA and its control is suboptimal, it is clear
that the control of MRSA is highly desirable and likely to be cost-effective. Any compromises in control are likely to be false
economies.
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Introduction
Methicillin-resistant Staphylococcus aureus (MRSA) is but one
of an increasing number of multiresistant organisms burden-
ing our healthcare systems [1]. It does, however, merit
special attention, for several reasons, namely: wave after
wave of different clones have ensured its spread to almost
every country; many strains are virulent; it can cause particu-
larly aggressive disease, even in healthy young people in the
community; it can spread in animals, often with major eco-
nomic impacts; and, perhaps most importantly, its resistance
spectrum often includes virtually all commonly used empirical
antibiotics, leading to severe difﬁculties in ensuring appropri-
ate treatment, with consequent poor outcome for patients
[2]. In some countries, most notably the UK, MRSA has
become an important political issue. The UK has among the
highest rates in Europe, and during the 2005 General Elec-
tion it was even suggested that concern about MRSA was a
barometer for concern about the state of the country in
general [3]. The last few years have seen unprecedented
expenditure on infection control in general and MRSA
control in particular, with setting of mandatory targets for
MRSA bacteraemia (MRSAB) [4].
Such broad-based, multifaceted national control strategies
seem to have had a beneﬁcial effect both in France [5] and
in England [6], at least on MRSAB rates, although it is less
certain what effects have been seen on background carriage
of MRSA or even other MRSA infections. Nevertheless,
there is a consistency in the increasing literature on the
beneﬁcial effects of active surveillance cultures on hospital
admission, as long as they are combined with appropriate
infection control precautions, both to avoid transmission
within the hospital and to reduce the burden of colonization
of positive patients [7].
In common with many other antibiotic-resistant infections
that seem to dominate the hospital-acquired infection (HAI)
agenda, MRSA infections represent an additional burden of
infection, not merely replacing infection with antibiotic-
susceptible S. aureus [8]. Thus, a hospital, region or country
reporting a prevalence rate of 50% MRSA for its S. aureus
bacteraemia (SAB) ﬁgures is describing a doubling in the
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number of SABs. This is certainly obvious from UK ﬁgures,
which do not show any reduction in methicillin-sensitive
S. aureus (MSSA) bacteraemia (MSSAB), despite the huge rise
in MRSAB over the past decade or more. Presumably, this
also applies to other S. aureus infections, although there is
no robust monitoring to provide this data. Certainly, it
argues strongly for including comparisons (case controls)
with no infection when calculating costs of MRSA infection.
Another complex factor that is virtually impossible to
adjust for is the issue of empirical therapy for MRSA infec-
tions. Early studies showed a doubling in mortality resulting
from MRSAB and other serious MRSA infections as compared
with MSSAB [9], almost certainly because of both delays in
administering appropriate therapy and the inferior efﬁcacy of
standard therapy for MRSA (vancomycin) when compared
with semisynthetic penicillins (SSPs) for MSSA [10]. In subse-
quent studies that might show less of a difference in mortality
and length of stay (LOS), these ﬁndings may be attributable to
improved outcome from the use of new MRSA antibiotics,
such as linezolid and daptomycin, or, more likely, the increas-
ing use of vancomycin for empirical treatment of MSSA
despite its well-known inferiority. No studies adjust costs for
the added disease burden of such empirical treatment strate-
gies that might lead to signiﬁcantly increased morbidity and
mortality in patients infected with MSSA but treated, at least
initially, with vancomycin. This is a hidden cost of MRSA that
could be signiﬁcant but remains unquantiﬁed.
Methods
This critical review of the MRSA economic literature follows
on from one with a similar title, written by one of the
authors [11], with an update of the literature.
The search terms used were identiﬁed from the latest
systematic review of the literature [12].
Clinical Signiﬁcance of MRSA
The spectrum of disease caused by MRSA is broadly similar
to that caused by MSSA, with one notable difference: MRSA
mostly causes HAIs, so there is often a preponderance of
foreign-body-associated and prosthesis-associated infections,
such as catheter-associated infections (mainly blood but also
urine), infective endocarditis, ventilator-associated pneumonia
and joint infections [13].
The clinical signiﬁcance of MRSA lies not only in the number
of infections that it causes (as discussed in the Introduction)
but, at least as importantly, in the effect that its presence
can have on empirical prescribing strategies and directed
prescribing for other infections, throughout the whole hospi-
tal. Most successful clones of MRSA are resistant not only to
all b-lactams, by deﬁnition, but also to macrolides and quinol-
ones, and some are even resistant to aminoglycosides. Thus,
if MRSA is to be covered in empirical regimens, then this
usually entails addition of an MRSA-speciﬁc agent, tradition-
ally vancomycin (or teicoplanin if available) or a new MRSA
agent such as linezolid or daptomycin [14]. Although the
price of glycopeptides has decreased dramatically in most
countries recently, owing to the broad availability of gener-
ics, their use necessitates therapeutic monitoring, both to
ensure efﬁcacy and to attempt to reduce toxicity. Nephro-
toxicity is particularly important. Moreover, increasing resis-
tance to glycopeptides is necessitating increased dosing of
glycopeptides, with concomitant increased toxicity, or
increasing use of newer, signiﬁcantly more expensive agents.
It is clear that this is a rapidly moving clinical area that may
make existing cost studies outdated [15].
A consideration of when to add speciﬁc MRSA therapy to
empirical regimens (and which agent) is a difﬁcult decision
that will depend on many factors, such as local prevalence of
MRSA, severity of infection, glycopeptide resistance rates,
MIC creep, availability of therapeutic monitoring, and costs of
acquisition of speciﬁc agents. The desire to avoid treatment
of serious MSSA infections with a glycopeptide may lead to
its addition to existing regimens that include a semi synthetic
penicillin (SSP), but there are conﬂicting data on the induction
of resistance with such combinations and no data on clinical
efﬁcacy, whereas it is quite clear that glycopeptides are infe-
rior to SSPs for treatment of serious MSSA infections [11].
Development of resistance to daptomycin and linezolid adds
a new, and so far unquantiﬁed, dimension to this complicated
picture [16,17].
Quality of the Literature
Our literature search identiﬁed 32 papers. Twenty-three
studies could be classed as either costing studies, to establish
the excess cost of MRSA infection or an estimate of the
national burden (n = 7), or economic evaluations comparing
the costs and beneﬁts of an intervention with the pre-exist-
ing service (n = 15). In this latter category, all but one study
evaluated screening in hospital, the exception being an
evaluation of cleaning [18].
On review of the studies, there were some notable fea-
tures. It often takes time to analyse and report the data on
interventions. The most recent clinical data were from 2007,
but more typically the studies reported interventions that
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took place in the early half of the last decade, and were
hence 7–8 years old. This raises concern about whether the
interventions being evaluated are still relevant. Of more con-
cern is whether the ‘status quo’ against which interventions
such as screening were compared are still relevant; for
example, a screening intervention might have halved the
infection rate in 2002 but, as compared with current practice
in 2010 (with heightened awareness of MRSA and resources
devoted to tackling the problem), it might offer a more mod-
est reduction. This may be a result of the evaluations being
relatively poorly funded. In ten cases a funding source was
declared, but in three cases it was explicit that the evaluation
was unfunded. In ten cases the journal did not require a
statement about funding or conﬂicts of interest, a neglect
that will surely have to be addressed soon.
The settings for the studies raise concerns about how
generalizable the results were. The economics studies took
place in eight different countries, with the USA contributing
nine studies and the UK ﬁve. Other countries tended to be
northern European (Germany three, The Netherlands two,
Belgium, France, and Finland), with Spain being the only
southern European country represented; the other study
was from Canada. This is important because the relevance of
studies carried out in one country to another healthcare
system is an issue; in other words, can the ﬁndings be
transferred? There are many reasons for being cautious: a
screening programme that is cost-effective at one level of
prevalence may not be cost-effective in a country with a
lower prevalence. It is widely recognized that costs of
healthcare differ, as do the severity of illness needed for a
patient to be admitted to hospital and their LOS. All of these
are arguments for being extremely cautious about taking
economics results out of context.
There may even be concern about generalizing the results
within a country: 19 of the 23 economics papers were based
on clinical studies, but in 17 cases the setting was a single
hospital, generally a tertiary-care centre. One of the
two exceptions considered only two hospitals [19]; the
remaining study used data from the entire German health-
care system [20]. In all cases, it was acute hospitals that
were considered.
Whereas 15 of the studies could be regarded as economic
evaluations of screening, they covered at least ten different
target groups. The most common was the whole of the
acute hospital (n = 4), followed by intensive care (n = 3) and
orthopaedics (n = 2). The other groups were emergency
admissions, high-risk patients, geriatrics, obstetrics, surgery
and vascular surgery. This raises the issue of whether
screening (or intervention more generally) is more cost-
effective in some settings than in others.
In terms of the clinical data underpinning the estimates of
savings in the evaluations of screening, ﬁve studies used a
‘before and after’ design. The other studies used a cohort
design, introducing estimates of resource savings from
sources such as expert opinion or assumptions (in one case,
based in part on rates in other countries). Of course, the
evaluation may have been constrained in what was possible,
and the evaluation may have been opportunistic. However,
these study designs are inherently weak. Over time there
has been growing awareness of the problem of MRSA infec-
tion, with a variety of ways of tackling the problem being
implemented. This makes reliance on pre-intervention rates
as a proxy for the current rate without the intervention at
best an overestimate and at worst invalid. Different assump-
tions were also made about savings for each infection
avoided. Among the 15 ﬁgures cited, the range was from
US$612 to US$118 415. Estimates of excess hospital stay
ranged from 4.5 days to 50 days.
Some of this variation would be expected; as stated above,
screening was performed in different areas of healthcare, and
we would not expect the savings from infections avoided in
obstetrics, geriatrics and intensive care to be the same. How-
ever, an important part of this variation was attributable to a
failure to adjust crude differences in costs for other factors;
as one study of bacteraemia infection noted, patients who
were infected had a signiﬁcantly longer hospital stay and
intensive-care unit (ICU) stay before the onset of the infec-
tion [21]. Some studies made such adjustments explicitly (e.g.
Resch et al. [20], Schultz et al. [22] and Gould et al. [23]),
thus avoiding the extreme values in some other studies (e.g.
West et al. [19] and Nixon et al. [24]). Of concern was the
fact that in 11 papers it was either not stated whether the
estimates of the savings per infection had been adjusted for
other factors or it was unclear whether this had been done.
Several papers quoted a saving from a previously published
study without reporting how it was derived (or, indeed,
whether it was for an MRSA infection type that was relevant
to the screening programme under evaluation).
In summary, there are a number of reasons to be extre-
mely cautious about the literature available. Evaluations
appear to have been carried out opportunistically alongside
change that was being implemented, without the beneﬁt of a
robust research design such as a randomized controlled trial.
The designs introduced to make comparisons are weaker
and may overestimate the beneﬁts. Evaluations are typically
set in one hospital, and may be comparing an intervention
with infection control practice that is up to a decade out-
of-date. Taking the ﬁndings from one setting and applying
them in another is fraught with difﬁculty, as the results are
likely to be dependent on the prevalence rate, treatment
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protocols, LOS, and cost structures of speciﬁc hospitals; in
addition, the judgement of analysts on factors such as the
savings per infection or quality-of-life impact of an infection
introduce further doubts. Many studies are very honest
about their limitations. A few studies represent several
aspects of good practice, such as that by Resch et al. [20],
who apply a case–control design to multiple hospitals.
Costs to Hospitals
Annually in the EU, MRSA infections have been estimated to
result in 1 million extra days of hospitalization and an attrib-
utable additional hospital cost of €380 million [25]. The public
concern about this organism, fuelled by politics and media
interest, has led to additional costs resulting from litigious
cases. Although there are no comprehensive ﬁgures for the
costs to hospitals from litigation, as to date these have been
out-of-court settlements, there have been a number of high-
proﬁle cases. The ﬁrst of these in the UK resulted in an out-
of-court settlement in the region of £400 000 (BBC website
report: http://news.bbc.co.uk/1/hi/health/6148546.stm (last
accessed 15 July 2010)). The case for compensation arises
from harm attributable to pain and suffering for the patient
and loss of earnings resulting from slow return to work as a
result of extended LOS in hospital. As clinical negligence is
hard to prove with MRSA, recent cases have used the Con-
trol of Substances Harmful to Health route, which requires
employers to control exposure to hazardous substances to
prevent ill-health. A test case is currently underway in the UK
that could have extensive implications for hospital costs in
the future. In addition to these potential costs, there are
actual costs already in existence associated with MRSA infec-
tion in hospitals, as these infections result in extended LOS
and the associated costs. Extended LOS attributable to HAI is
the measure used by most studies for hospital costs. The
number of bed-days lost to a case of HAI has been deemed
to be an appropriate outcome measure for costs [26]. Bed-
day costs include the costs for a patient being in a bed for a
day (with the on-costs for staff and ﬁxed infrastructure such
as power and information technology). Studies published
internationally indicate a marked variation in the estimates for
the extended LOS costs. A US study of 1 355 347 admissions
in 55 hospitals estimated a cost per infection of $12 197, but
studies in France indicate a mean cost per case of $39 500
[27]. Much of this variation may be associated with the con-
text of different healthcare systems, but even intracountry
comparisons show variation, much of which is attributable to
methodological issues, such as comparing costs with matched
MSSA cases, or with patients without infection at all.
A small but well-designed retrospective cohort study [21],
using a propensity scoring approach to adjust for some of
the confounders identiﬁed previously, indicated that the cost
before infection for MRSAB was higher than that in patients
with an MSSAB, and that in these cases of infection there
was no difference; that is, the costs were attributable to a
bloodstream infection (BSI) rather than being organism-spe-
ciﬁc. Previous authors [28,29] have found additional marginal
costs with MRSAB of $3826 to $27 000 per patient, attribut-
able to delay in diagnosis, suboptimal therapeutic options,
and cost of ICU stay. Interestingly, those with MRSA were
more likely to be in the ICU pre-BSI, and therefore to stay
in the ICU thereafter. The most recent study examining the
whole hospital excess costs of MRSA indicated, following
adjustment for confounding comorbidities with the Charlson
index, adjusted costs of $51252 to $84 436 for MRSA as
compared with $30 158 to $59 245 for MSSA [30]. The
authors noted that patients with MRSA were more likely to
have BSIs, respiratory tract infections and urinary tract infec-
tions, whereas MSSA was more likely to involve bone and
joints, eyes, ears and skin soft tissue infection (SSTI). Com-
parisons between studies are often not possible, because of
the different types of infection included or excluded within
the analyses. Costs will vary with the severity of infection;
thus, bacteraemias may be more costly than pneumonias;
which may, in turn, be more costly than surgical infections
arising from MRSA. Nonetheless, resistance has been inde-
pendently associated with higher costs [30], and there is
therefore a need to focus on these resistant infections.
It is recognized that reductions in costs associated with
infections are opportunity costs. Fixed costs in healthcare do
not change if HAI rates are lowered, as this results in spare
capacity in the hospital, which can be redeployed for new
patients, meaning that actual costs may increase overall. The
marginal number of bed-days released by infection preven-
tion and control can be used to meet the other demands,
such as waiting lists, previously unmet health demands or the
pursuit of quality. Included in these hospital costs are inter-
ventions to control MRSA, such as cohorting and isolation. A
well-conducted review of the economic consequences [31]
of MRSA concluded that the total average cost per infected
MRSA case was $12 216, with hospitalization accounting for
the majority of this (81%). The remainder of the costs of an
MRSA infection arise from consumables, outwith the bed-day
cost, used to treat an infection. This includes additional costs
for screening, use of personal protective equipment and the
costs of antibiotics. Antibiotic use, in terms of suppression of
colonization and treatment of infection, also becomes an
important consideration in the economic argument for inter-
vention with resistant organisms, as there are unintended
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consequences, such as future resistance mechanisms, of their
use that can result in further economic consequences for
healthcare. Each of these will be discussed in turn.
Costs for Infection Control
A well-conducted review of the economics of MRSA and the
associated interventions indicated that the additional controls
amounted to about 20% of the costs of the infection, result-
ing in an additional cost per case for control of $2400 [31].
This included barrier precautions (13%), antimicrobial ther-
apy (4%) and laboratory investigations (2%).
The role of screening in reducing MRSA infection has
become a much debated topic in the infection literature over
the last decade, in terms of both clinical effectiveness and
cost-effectiveness. A much needed systematic review [12] of
the evidence for screening concluded that the most clinically
effective approach was clinical risk assessment with targeted
laboratory testing of those at risk; however, the most cost-
effective approach was universal laboratory testing of all
admissions to hospital. Screening programmes therefore have
economic consequences on two levels: the costs associated
with the screening itself (laboratory costs, consumables and
clinical staff costs), and then the costs of treating or manag-
ing those with positive ﬁndings, who would not have been
identiﬁed otherwise (isolation, potential extended stay and
decolonization costs).
Laboratory testing for MRSA has continued to evolve over
the last decade, with new emerging technologies promising fas-
ter turn-around times. These technologies have cost conse-
quences. The health technology assessment (HTA) [12]
indicated that PCR technologies were cost-prohibitive and
actually did not prove to be more clinically effective, as the
sensitivity and speciﬁcity of the test resulted in more false-
positive cases being placed in isolation, and it therefore had
less of an impact on outcome. Since this review was published,
there have been a number of published studies indicating that
PCR may be effective in further reducing MRSA prevalence. A
new HTA from Canada [32], evaluating PCR for MRSA screen-
ing in hospitals, concluded that PCR demonstrated some
advantage in clinical effectiveness (high screening test accuracy
and lower colonization, infection and transmission rates) over
chromogenic agar; however, it concluded that questions
remain over cost-effectiveness. This ﬁnding has been rein-
forced in two recent studies published in this journal [33,34].
Uncertainty therefore remains about the optimal screening
test to minimize the number of adverse events cost-effectively.
Isolation as an intervention and the costs associated with
it can be lost in the average bed-day costs used by many
studies. Isolation facilities are a ﬁxed resource for hospitals,
and there are competing demands for their use. The oppor-
tunity cost associated with isolation has been estimated at
€406 a day, consisting of isolation measures (€25), extra
healthcare workers (€290), personal protective equipment
(€52) and additional cleaning (€40) [35]. When these facili-
ties are not available, the practice of cohorting is deployed
to prevent cross-transmission of colonization. Nurse cohort-
ing requires dedicated nursing staff for a cohort of patients
for each shift, and therefore more resources. This is often
overlooked when determining average bed-day costs for
HAI, and not achieved in practice, owing to resource con-
straints. The latest HTA [12] indicates that cost-effectiveness
varies according to the pre-emptive isolation policy and the
proportion of contacts per visit between a healthcare
worker and a patient. Very few studies acknowledge these
costs.
Studies examining the impact of screening on outcome
have used a variety of economic approaches, thus making
comparisons difﬁcult. Screening for MRSA and the associated
interventions was projected to save 935 lives and $231 mil-
lion in net medical costs in the USA [27]. The inclusion of
molecular typing was calculated to prevent 270 infections
and save $2.2 million in net healthcare costs annually. In
Spain [36], the economic burden of MRSA infections in a
single hospital annually was estimated at €101 000, set
against the cost of a screening programme of €10 261. It
was concluded that screening would be justiﬁed if four
MRSA infections were prevented in a year in the hospital. In
the UK, costs for screening have been suggested to be less
than the estimates of the latest systematic review of the
evidence [37], and there have been calls for a universal
approach to screening as a result. A recent large multicentre
cohort study [38] of universal screening found a reduction
in MRSA as well as overall S. aureus infections, and con-
cluded that assessment of the ﬁnancial impact of an MRSA
control programme should include a control group with no
S. aureus as the comparator. Use of MSSA as the compara-
tor suggested no ﬁnancial gain in reducing MRSA infection,
an outcome not seen when the prevention of MRSA disease
was the control.
Costs of interventions associated with an outbreak of
MRSA in a tertiary hospital in Finland [39] indicated addi-
tional screening, contact isolation and related costs of
€386 062. Interestingly, the authors concluded that screening
was an additional cost, and that the control measures were
not necessarily effective during the study period, but recom-
mended continuation of these measures to reduce and main-
tain the MRSA low-endemicity levels (<1%). Making the case
for infection control means suggesting the re-allocation of
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scarce resources away from the supply of other health-
producing activity; therefore, the beneﬁts, in terms of both
public health and cost, must be clear in order to inform
policy.
Costs to Patients and Society
The perspective of the economic evaluation determines the
range of costs and beneﬁts that should be included. The
most common perspectives are: (i) the healthcare system;
and (ii) societal (i.e. including all costs and beneﬁts, no mat-
ter where they occur). Other perspectives are possible (e.g.
the public sector and the hospital) but rarer. The analyst has
a choice over which perspective to use, but should be aware
that perspectives need to be matched to the decision-maker.
For example, someone responsible for the antibiotics budget
will have no incentive to consider savings on lost working
time elsewhere in the economy; on the other hand, a minis-
ter for health will have wider concerns than a narrow hospi-
tal point of view.
Evaluations of MRSA programmes face a dilemma: if they
exclude non-healthcare costs, they understate the problem,
but if they include them, the analysis becomes of consider-
ably less interest to healthcare decision-makers. In the
papers that we reviewed, the perspective invariably centred
on the hospital; other healthcare costs were quantiﬁed in a
few cases. Still rarer was an example of a study that quanti-
ﬁed costs to patients. There was only one example [40] that
included costs of lost working time (in terms of an hourly
wage rate), and no details were provided of how many hours
of work were assumed to be lost. Some other studies
mentioned that broader costs and savings existed, but did
not attempt to quantify them.
Quality-adjusted Life-years (QALYs)
The economic evaluations that we reviewed almost all
compared the costs of the programme with the estimated
reduction in MRSA infections, and then attached a value
to the savings on resources; if the value of the savings
exceeded the value of resources used in the intervention,
the programme was judged to be cost-effective.
In two cases, the evaluation also tried to quantify mortal-
ity beneﬁts from avoiding infections. van Rijen and Kluytmans
[41] estimated that 36 bacteraemia infections avoided would
have led to ten deaths. Wenzel et al. [42] estimated that a
death from MRSAB would result in the loss of 10 years of
life. Neither study appeared to include these estimates in its
ﬁnal economic calculation, which still relied on the values of
savings vs. the value of resources used.
QALYs are a way of including the quality-of-life and survival
effects of MRSA interventions in an economic evaluation [43]
Only two of the studies that we reviewed estimated QALY
gains. In one study of screening for MRSA in an obstetrics set-
ting [40], the analysts assumed that when the woman suffered
from an infection, her quality of life was reduced by 0.35
(where 1 equals full health and 0 equals a state as bad as being
dead); this lasts for 1 year, and she then returns to full health.
No reference was provided for this ﬁgure, and it appears to
have been an assumption on the part of the authors of the
paper. In fact, 0.35 is a large reduction, more than would usu-
ally be assumed for the effect of a stroke in later life.
In the other study that used QALYs, screening was being
evaluated in the context of a vascular surgery unit, with the
typical patient being 73 years of age [44]. The quality-of-life
values shown in Table 1 were used.
The ﬁgure for graft infection was from ‘expert consulta-
tion’; other ﬁgures came from four previously published
studies. It was unclear what method was used in these
studies or whether the values were consistent. The duration
over which the quality of life lost was applied appeared to be
determined by assumption; the duration of the impact of an
amputation seems particularly surprising. Once again, the
quality-of-life loss is quite large: for example, the loss result-
ing from having a urinary tract infection is similar to the
ﬁgure for an acute myocardial infarction.
Thus, whereas the two studies deserve credit for using
the QALY approach, they are both open to criticism. Both
used values that are open to challenge, and because they are
based on assumptions or are selected from previously pub-
lished studies without any clear rationale, they are not easy
to defend. Both may have overestimated the quality-of-life
loss resulting from having an infection, raising concerns that
the beneﬁt of MRSA interventions may have been overesti-
mated. Similarly, the duration of the effect on quality of life
seems to have been entirely based on assumption. Properly
designed studies of the quality of life of patients with MRSA
infection are urgently required.
TABLE 1. Quality-of-life adjustments
Quality of life Duration (days)
Wound infection 0.642 10–14
Graft infection 0.53 28–42
Amputation 0.44 10–14
Stump infection 0.3 10–14
Line infection 0.642 14–28
Urinary tract infection 0.73 10–14
Pneumonia 0.58 10–14
1 = full health
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Estimating Costs to Inform Policy
Decision-making
This review has identiﬁed marked variation in the estimates
of costs attributable to MRSA and the interventions associ-
ated with them. Healthcare resources are scarce, and deci-
sions need to be made that enable delivery of quantiﬁable
health beneﬁts. Decisions on the public health beneﬁt of
interventions for infection control need to be made in the
broader medical care expenditure context. Many of the stud-
ies published in the last 10 years in infection control have
acknowledged the importance of costs, but have failed to
address them within the context of their study. Others have
based infection prevention and control intervention recom-
mendations on partial economic analysis, examining the gross
cost of HAI, and not addressing cost-effectiveness. Accurate
estimates of the extra cost of implementing infection control
strategies have been called for recently [26]. This review
recognizes that data are now emerging that question the
validity of previous estimates of costs [45,46].
A recent large economic analysis of data from 26 Euro-
pean countries [47] indicated that there was a statistically
signiﬁcant relationship between healthcare expenditure in
individual countries and the epidemiology of MRSA within
those countries. Clinically and cost-effective infection preven-
tion and control programmes, inclusive of antimicrobial
prescribing, are needed to prevent these costly infections.
Infection control specialists and researchers in HAI need to
engage with health economics in this agenda, if the business
case for infection prevention and control interventions is to
be taken seriously by policy-makers.
Conclusions
The literature on the costs of MRSA and its control is sub-
stantial, but unsatisfactory. Nevertheless, there is a consis-
tent message from these studies that admission surveillance
cultures and barrier precautions for MRSA-positive patients
are both efﬁcacious in its control and are also likely to be
highly cost-effective. The more screening there is, the larger
the reduction in MRSA that is likely to be achieved, and the
higher the prevalence of MRSA, the greater the impact of
screening will be. Moreover, from a clinical viewpoint, con-
trol of MRSA is highly worthwhile, not only from the point
of view of reducing the substantial clinical burden of MRSA,
but also for improving the treatment of other infections by
being able to avoid the use of glycopeptides. Future research
should concentrate on more methodical, well-designed and
robust intervention studies rather than the largely observa-
tional, uncontrolled studies that ﬁll the existing literature.
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